A novel C-terminal Hsp90 inhibitor KU758 synergizes efficacy in combination with BRAF or MEK inhibitors and targets drug-resistant pathways in BRAF-mutant melanomas

Keyphrases

• Drug Resistance 100%
• Targeted Drugs 100%
• Melanoma 100%
• BRAF Inhibitor (BRAFi) 100%
• BRAF-mutant Melanoma 100%
• Synergize 100%
• Hsp90 Inhibitor 100%
• Multidrug-resistant 100%
• MEK Inhibitor (MEKi) 100%
• Resistance Pathways 100%
• Inhibitor Drug 100%
• Protein-resistant 33%
• Tumor 33%
• Cell Wall Proteins 33%
• Mitogen-activated Protein Kinase 33%
• Metastatic Disease 33%
• Cell Proliferation 33%
• Targeted Therapy 33%
• Multiple Drugs 33%
• Skin Cancer 33%
• Protein-based 33%
• First Year 33%
• Treatment Efficacy 33%
• 5-year Survival 33%
• New Patients 33%
• Multiple Proteins 33%
• Melanoma Cells 33%
• Pathway Inhibitors 33%
• Protein Expression 33%
• Standard of Care 33%
• Novel Therapeutics 33%
• Melanoma Treatment 33%
• Molecular Chaperone 33%
• FDA-approved Drugs 33%
• Western Blot Analysis 33%
• Chaperone Function 33%
• Chaperone Hsp90 33%
• Major Resistance 33%
• Chemotherapy-induced 33%
• Heat Shock Response 33%
• Advanced Disease 33%
• Novel Inhibitors 33%
• Vemurafenib 33%
• Targeted Immunotherapy 33%
• Inhibition of Cell Migration 33%
• Inhibitor Combination 33%
• Targeted Chemotherapy 33%
• In Vitro Proliferation 33%
• Cobimetinib 33%
• BRAF mutant 33%
• Early Support 33%

Medicine and Dentistry

• Nodular Melanoma 100%
• Carboxy Terminal Sequence 100%
• MEK Inhibitor 100%
• Hsp90 Inhibitor 100%
• Disease 50%
• Drug Resistance 50%
• In Vitro 33%
• Neoplasm 16%
• Cell Migration 16%
• Mitogen-Activated Protein Kinase 16%
• Metastatic Carcinoma 16%
• Cell Proliferation 16%
• Western Blot 16%
• Combination Therapy 16%
• Skin Cancer 16%
• Melanoma Cell 16%
• Targeted Therapy 16%
• Cell Protein 16%
• Protein Expression 16%
• Survival Rate 16%
• Immunotherapy 16%
• Chaperone 16%
• Vemurafenib 16%
• Cobimetinib 16%
• Heat Shock Response 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Melanoma 100%
• Mitogen Activated Protein Kinase Kinase Inhibitor 100%
• Heat Shock Protein 90 Inhibitor 100%
• Disease 42%
• Drug Resistance 42%
• Chemotherapy 28%
• Neoplasm 14%
• Combination Therapy 14%
• Mitogen Activated Protein Kinase 14%
• Skin Cancer 14%
• Immunotherapy 14%
• Metastasis 14%
• Western Blot 14%
• Survival Rate 14%
• Chaperone 14%
• Vemurafenib 14%